Table 5.
Ongoing phase-III randomized trials
| Study | Country | No. registration | Standard arm | Experimental arm | Patients (n) |
| Neoadjuvant chemoradiotherapy | |||||
| EORTC 22114 - 40111 TOP GEAR study | Europe | NCT01924819 | ECC/ECF preoperative CT | ECC/ECF preoperative CT and RTCT preoperative | 752 |
| Perioperative chemotherapy | |||||
| MAGIC-B/ST03 study | United Kingdom | NCT00450203 | ECC perioperative CT | ECC + bevacizumab perioperative CT | 1100 |
| PRODIGY trial | South Korea | NCT01515748 | S-1 adjuvant CT | Neoadjuvant DOS CT and S-1 postoperative CT | 640 |
| Adjuvant chemotherapy | |||||
| ARTIST II Trial | South Korea | NCT01761461 | S-1 adjuvant CT (arm 1) | SOX adjuvant CT (arm 2), S-1 and RT adjuvant (arm 3) | 1000 |
| Adjuvant chemoradiotherapy | |||||
| CRITICS Trial | The Netherlands | NCT00407186 | ECC perioperative CT | ECC preoperative CT and RTCT postoperative | 788 |
CT: Chemotherapy; RTCT: Radiochemotherapy; ECC: Epirubicin, cisplatin and capecitabine; ECF: Epirubicin, cisplatin, and fluorouracil; DOS: Docetaxel, oxaliplatin, and S-1; SOX: S-1 and oxaliplatin.